Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

NCT05050162 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT05050162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05050162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Lead sponsor
NRG Oncology
Phase
Phase 2/3
Overall status
Suspended
Start date
February 1, 2022
Completion date
February 9, 2027
Enrollment
1,714 (estimated)
Sites
370

Conditions

As the registry lists them; a condition with its own page is linked.

advanced head and neck squamous cell carcinoma, advanced hypopharyngeal squamous cell carcinoma, advanced laryngeal squamous cell carcinoma, advanced oropharyngeal squamous cell carcinoma, clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, clinical stage iv hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, stage iii head and neck cutaneous squamous cell carcinoma ajcc v8, stage iii oropharyngeal (p16-negative) carcinoma ajcc v8, stage iv head and neck cutaneous squamous cell carcinoma ajcc v8, stage iv oropharyngeal (p16-negative) carcinoma ajcc v8